Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.41 |
| ▸ | HSD17B13 | Q7Z5P4 | 4/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396888 | 1.00 | SLC6A9 (0.41) | SLC6A9KCNH2HSD17B13SLC6A5CYP2D6 | |
| SCHEMBL2399367 | 0.88 | SLC6A9 (0.46) | SLC6A9KCNH2HSD17B13SLC6A5CYP2D6 | |
| SCHEMBL2400853 | 0.88 | SLC6A9 (0.44) | SLC6A9KCNH2HSD17B13SLC6A5CYP2D6 | |
| SCHEMBL2399391 | 0.86 | SLC6A9 (0.44) | SLC6A9KCNH2HSD17B13SLC6A5CYP2D6 | |
| SCHEMBL2400290 | 0.85 | NOTUM (0.45) | NOTUM | |
| SCHEMBL2398360 | 0.85 | NOTUM (0.45) | NOTUM | |
| SCHEMBL2396008 | 0.84 | LPAR1 (0.38) | NOTUM | |
| SCHEMBL2216720 | 0.84 | LPAR1 (0.38) | NOTUM | |
| SCHEMBL2214205 | 0.84 | SLC6A9 (0.42) | SLC6A9KCNH2HSD17B13SLC6A5CYP2D6 | |
| SCHEMBL2399616 | 0.83 | SLC6A9 (0.42) | SLC6A9KCNH2HSD17B13SLC6A5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | claimed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | SLC6A9 528/4885KCNH2 362/4885HSD17B13 924/4885 |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | SLC6A9 511/4885KCNH2 145/4885HSD17B13 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.